Oral Drug Highly Active in Rare Blood Cancers With FGFR1 Rearrangements

Last updated: September 9, 2025 8:25 pm

0 Min Read

MedPage Today) — Most patients with myeloid/lymphoid neoplasms with FGFR1 rearrangements receiving pemigatinib (Pemazyre) experienced complete responses in the phase II FIGHT-203 trial.
Among 45 patients analyzed for efficacy, the overall complete…

Leave a Reply Cancel reply

Ads Blocker Detected & This Is Prohibited!!!

We have detected that you are using extensions to block ads and you are also not using our official app. Your Account Have been Flagged and reported, pending de-activation & All your earning will be wiped out. Please turn off the software to continue

Refresh Screen

Ads Blocker Detected & This Is Prohibited!!!

Refresh Screen

Top Stories

NDLEA arrests 280 drug suspects in Oyo State, secures 43 convictions in 8 months

Thousands of ecommerce sites at risk after popular CMS targeted by malware attack — here’s what you need to know

Nearly 2 million people watched this spellbinding video of a mini PC being built from a slab of aluminium to a complete computer

Stay Connected

Oral Drug Highly Active in Rare Blood Cancers With FGFR1 Rearrangements

Leave a Reply Cancel reply

Related Stories

Blue States That Sued Kept Most CDC Grants, While Red States Feel Brunt of Trump Clawbacks

7 Best Face Creams With SPF of 2025, According to Derms

4 Signs You Have an Avoidant Attachment Style, According to Experts

Fitness Training Helps the Mind After Stroke

AI Chatbots Need to Fix Suicide-Related Responses, Study Says

An Insurer Agreed To Cover Her Surgery. A Politician’s Nudge Got the Bills Paid.

Patients With Advanced Cancer Report Disconnect in Desired Versus Delivered Care

More Medicare Patients Are Leaving the Hospital Against Medical Advice